Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

NCT02672475 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions

DRUG: Galunisertib
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]